Dr Danny Nguyen speaks to ecancer about managing patients with EGFR exon 20 insertion mutated NSCLC, and EGFR TKI toxicity.
Dr Nguyen discusses the comparative clinical outcomes between EGFR Exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors.
He also mentions other emerging data from recent conferences regarding the treatment of EGFR exon 20 ins mutation NSCLC patients.
He also looks at the data on managing EGFR TKI toxicity from ESMO and WCLC 2021, including toxicity profiles of mobocertinib, DZD9008, and amivantamab.
He concludes by talking about what the future looks like for the treatment of EGFR exon 20 ins NSCLC.
This programme has been supported by an unrestricted educational grant from Takeda.